Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a

  • Biomol Ther (Seoul). 2014 Jan;22(1):41-6. doi: 10.4062/biomolther.2013.108.
Jaehyoung Song  1 ,  Sang-Gu Yeo  2 ,  Eun-Hye Hong  3 ,  Bo-Ra Lee  3 ,  Jin-Won Kim  4 ,  Jeonghoon Kim  5 ,  Hyeongun Jeong  5 ,  Yongsoo Kwon  3 ,  Hyunpyo Kim  3 ,  Sangwon Lee  4 ,  Jae-Hak Park  6 ,  Hyun-Jeong Ko  3
Affiliations
  • 1. Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951 ; College of Pharmacy, Kangwon National University, Chuncheon 200-701.
  • 2. Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951 ; Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742.
  • 3. College of Pharmacy, Kangwon National University, Chuncheon 200-701.
  • 4. Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951.
  • 5. Ahn-Gook Pharmaceutical Co., LTD, Seoul 150-953, Republic of Korea.
  • 6. Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742.
PMID: 24596620 DOI: 10.4062/biomolther.2013.108
Abstract

Enterovirus 71 (EV71) is the predominant cause of hand, foot and mouth disease (HFMD). The Antiviral activity of hederasaponin B from Hedera helix against EV71 subgenotypes C3 and C4a was evaluated in vero cells. In the current study, the Antiviral activity of hederasaponin B against EV71 C3 and C4a was determined by cytopathic effect (CPE) reduction method and western blot assay. Our results demonstrated that hederasaponin B and 30% ethanol extract of Hedera helix containing hederasaponin B showed significant Antiviral activity against EV71 subgenotypes C3 and C4a by reducing the formation of a visible CPE. Hederasaponin B also inhibited the viral VP2 protein expression, suggesting the inhibition of viral capsid protein synthesis.These results suggest that hederasaponin B and Hedera helix extract containing hederasaponin B can be novel drug candidates with broad-spectrum Antiviral activity against various subgenotypes of EV71.

Keywords
Antiviral activity; Enterovirus 71; Hand foot and mouth disease; Hedera helix; Hederasaponin B.
Products